The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dupilumab for the treatment of dermatologic adverse events associated with MEK and EGFR inhibitors.
 
Stephanie Gu
No Relationships to Disclose
 
Stephen W Dusza
No Relationships to Disclose
 
Ira J. Dunkel
Consulting or Advisory Role - Apexigen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Day One Therapeutics; Fennec Pharma; Pyramid Biosciences; QED therapeutics; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Novartis (Inst)
 
Alexander E. Drilon
Stock and Other Ownership Interests - Treeline Biosciences
Honoraria - Answers in CME; Associazione Italiana Oncologia Toracica (AIOT); AstraZeneca; BeiGene; Chugai Pharma; Clinical Care Options/NCCN; Helsinn Therapeutics; i3 Health; IASLC; Ignyta/Genentech/Roche; Liberum; Loxo/Bayer/Lilly; Lung Cancer Research Foundation; Lungevity; NIH; OncLive/MJH Life Sciences; PER; Pfizer; Remedica; Remedica; Research to Practice; RV Mais; Sirio Libanes Hospital; TP Therapeutics; Verastem
Consulting or Advisory Role - 14ner Oncology/Elevation Oncology; Abbvie; Amgen; Applied Pharmaceutical Science; Archer; AstraZeneca; Axis Pharma; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Clinical Care Options; Clinical Care Options; EMD Serono/Merck; Entos; EPG Health; Exelixis; Genentech/Roche; Hengrui Therapeutics; Ignyta; Janssen; Journal of the National Comprehensive Cancer Network; Liberum; Lilly; Loxo; Med Learning; Medscape; Melendi; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; MORE Health; Novartis; Nuvalent, Inc.; Ology Medical Education; Ology Medical Education; PeerView; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda/Millennium; touchIME; Treeline Biosciences; Tyra Biosciences
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - Boehringer Ingelheim; GlaxoSmithKline; Merck; Merus; Pfizer; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva
 
Mario E. Lacouture
Stock and Other Ownership Interests - Oncoderm (I)
Honoraria - Apricity Health; AstraZeneca; Deciphera; Hoth Therapeutics; Incyte; Innovaderm; Janssen; Kinnate Biopharma; Kintara Therapeutics; Kintara Therapeutics; L'Oreal; La Roche-Posay; Loxo; Lutris; MJH Associates; Nanology; Novartis; Novocure; OnQuality Pharmaceuticals; RBC consultants; Relay Therapeutics; Repare Therapeutics; Roche/Genentech; Seagen; Seattle Genetics/Astellas; Trifecta; Tyra Biosciences
Consulting or Advisory Role - Apricity Health; AstraZeneca; Deciphera; Genentech; Incyte; Innovaderm; Janssen Research & Development; Kinnate Biopharma; Kintara Therapeutics; Kintara Therapeutics; La Roche-Posay; Loxo; Loxo; Lutris; Novartis; Novocure; OnQuality Pharmaceuticals; Relay Therapeutics; Repare Therapeutics; Repare Therapeutics; Roche; Roche; Seagen; Tyra Biosciences
Research Funding - AstraZeneca/MedImmune (Inst); Columbia University (Inst); Lutris (Inst); Lutris (Inst); National Jewish Health (Inst); Novartis (Inst); novocure (Inst); novocure (Inst); OnQuality Pharmaceuticals; OnQuality Pharmaceuticals (Inst); Paxman (Inst)
Other Relationship - Oncoderm (I)
(OPTIONAL) Uncompensated Relationships - Oncoderm
 
Alina Markova
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Research Funding - Incyte